retatrutide fda status Retatrutide, an experimental weight-loss drug, has not been approved by the FDA. But, doctors and nurse practitioners in clinics across the country are prescribing it anyway, a CBS News investigation found. @adamyamaguchi Would you wait for #retatrutide

Wall Street Analysts Goldman Sachs predicts that the oral GLP-1s (including oral Wegovy, Lillys orforglipron, and other pipeline products) will capture only a combined 24% of the GLP-1 market by 2030

Clustering was carried out by the Seurat functions FindNeighbors and FindClusters

Private Insurance Coverage in Canada Private insurance offers better coverage than provincial plans, but better doesnt mean good. Approximately 40-55% of private insurance plans in Canada provide some level of coverage for obesity medications based on claims data from 2024-2025

A study of 30 patients with type 2 diabetes treated for 8 weeks showed measurable reductions in CD62p (a marker of platelet activation) and PAC-1 (a marker of glycoprotein IIb/IIIa complex activation, the final common pathway of platelet aggregation)

However, survodutide acts on multiple metabolic pathways, so it could be useful beyond its appetite-suppressing effects, Perez noted